Literature DB >> 19925053

Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.

Preetha Markose, Ezhilarasi Chendamarai, Poonkuzhali Balasubramanian, Shaji Ramachandran Velayudhan, Vivi M Srivastava, Vikram Mathews, Biju George, Auro Viswabandya, Alok Srivastava, Mammen Chandy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19925053     DOI： 10.3109/10428190903332486

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  6 in total

1.  ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.

Authors:  Abdalla Awidi; Nidaa Ababneh; Ahmad Magablah; Nazzal Bsoul; Razan Mefleh; Lina Marei; Salah Abbasi
Journal:  Genet Test Mol Biomarkers       Date:  2012-09-25

Review 2.  Chronic Myeloid Leukemia in India.

Authors:  Prasanth Ganesan; Lalit Kumar
Journal:  J Glob Oncol       Date:  2016-07-20

3.  Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A Single-Center Experience in Thailand.

Authors:  Nittaya Limsuwanachot; Adcharee Kongruang; Budsaba Rerkamnuaychoke; Roongrudee Singdong; Pimjai Niparuck; Saengsuree Jootar; Teerapong Siriboonpiputtana
Journal:  Asian Pac J Cancer Prev       Date:  2020-07-01

4.  Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: Indian perspective.

Authors:  K Ghosh
Journal:  J Postgrad Med       Date:  2022 Apr-Jun       Impact factor: 1.566

5.  BCR-ABL1 kinase domain mutation analysis by next generation sequencing detected additional mutations in chronic myeloid leukemia patients with suboptimal response to imatinib.

Authors:  Esther Sathya Bama Benjamin; Niveditha Ravindra; Bharathi Murugan Rajamani; Senthamizhselvi Anandan; Bagavathi Kausalya; Vidya Veldore; Vikram Mathews; Shaji Ramachandran Velayudhan; Poonkuzhali Balasubramanian
Journal:  Leuk Lymphoma       Date:  2021-01-22

6.  Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients.

Authors:  Bharathi M Rajamani; Esther Sathya Bama Benjamin; Aby Abraham; Sukanya Ganesan; Kavitha M Lakshmi; Senthamizhselvi Anandan; Sreeja Karathedath; Savitha Varatharajan; Ezhilpavai Mohanan; Nancy Beryl Janet; Vivi M Srivastava; Shaji Ramachandran Velayudhan; Uday P Kulkarni; Anup J Devasia; N A Fouzia; Anu Korula; Biju George; Alok Srivastava; Vikram Mathews; Poonkuzhali Balasubramanian
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.